



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**United States Patent Application of:**

**Applicant:** DeVico, et al.

**Application No.:** 09/684,026

**Date Filed:** October 6, 2000

**Title:** VIRUS COAT  
PROTEIN/RECEPTOR  
CHIMERAS AND METHODS  
OF USE

**Docket No.:** 4115-144 RCE

**Examiner:** U. Winkler

**Art Unit:** 1648

**Conf. No.:** 3193

**Customer No.:** 23448

**23448**

**EXPRESS MAIL CERTIFICATE**

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to the Mail Stop RCE, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 and Express Mailed under the provisions of 37 CFR 1.10.



Candace White

December 30, 2003

Date

EV204080781US

Express Mail Label Number

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop RCE  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.


- ☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☐ c. Attached is our check no. \_\_\_\_\_ in the amount of \$\_\_\_\_\_ in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check no. \_\_\_\_\_ in the amount of \$180.00 in payment of the petition fee under 37 C.F.R. §1.17(i)(1). Please credit or debit Deposit Account No. \_\_\_\_\_ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.
- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).

Respectfully submitted,



Marianne Fuierer  
Reg. No. 39,983  
Attorney for Applicant

INTELLECTUAL PROPERTY/  
TECHNOLOGY LAW  
Telephone: (919) 419-9350  
Fax: (919) 419-9354  
Attorney Ref: 4115-144

CFORM PTO-1449 US Dept. of Commerce Patent and Trademark Office  <b>SUPPLEMENTAL          INFORMATION DISCLOSURE STATEMENT</b> (use several sheets if necessary)		<b>ATTORNEY DOCKET NO.</b> 4115-144 RCE		<b>SERIAL NO.</b> 09/684,026				
		<b>APPLICANT</b> DeVico et al.						
		<b>FILING DATE</b> October 6, 2000		<b>GROUP</b> 1648				
<b>U.S. PATENT DOCUMENTS</b>								
		<b>PATENT NUMBER</b>	<b>ISSUE DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE IF APPROPRIATE</b>	
<b>FOREIGN PATENT DOCUMENTS</b>								
		<b>DOCUMENT NUMBER</b>	<b>PUBLICATION DATE</b>	<b>COUNTRY</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>TRANSLATION YES      NO</b>	
	AH	WO94/26305	11/24/1994	PCT			X	
	AI	WO92/05799	04/16/1992	PCT			X	
	AJ	WO98/47916	10/29/1998	PCT			X	
	AK	WO93/15750	08/19/1993	PCT			X	
	AL	0 325 262 A2	07/26/1989	Europe			X	
<b>OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)</b>								
	AM	Rizzuto, Carlo D., et al. "A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding." Science, Vol. 280, (1998), pp. 1949-1953.						
	AN	Sells, Mary Ann, et al. "Epitope-tag vectors for eukaryotic protein production." Gene, Vol. 152, (1995), pp. 187-189.						
	AO	Sullivan, Nancy, et al. "CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization." Journal of Virology, (1998), pp. 4694-4703.						
<b>EXAMINER</b>					<b>DATE CONSIDERED</b>			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.								